Monoclonal antibodies with high speci®city for prostate tissue are of interest for prostate cancer research and treatment. Reactivity and speci®city of a new murine monoclonal antibody, 107-1A4, was assessed by immunohistochemistry, ELISA and indirect immuno¯uorescence (IDIF). 107-1A4 stained all normal and malignant prostate tissue specimens while reactivity to non-prostate tissue was limited to the tubules of the normal kidney and renal cell carcinoma. Twenty two human cell lines were included in the reactivity survey; only the immunogen prostate cancer line LNCaP reacted with 107-1A4. Seminal plasma proteins PSA, PAP, PSMA, and PSP-94 were determined not to be the 107-1A4 antigen.
Introduction
Over the past 15 y, there have been several attempts to generate monoclonal antibodies (Mabs) reactive with prostate cancer (CaP). Some of the Mabs resulting from these efforts were utilized as immunodiagnostic and immunohistochemical reagents, while a select few were utilized in trials of in vivo tumor targeting. Of those used to target CaP, only the Mab 7E11-C5 which is reactive with prostate speci®c membrane (PSMA) showed signi®-cant promise. 1 Nevertheless, CaP remains a theoretically attractive target for in vivo antibody applications because: (a) unlike nearly all other tumors, the targeted antigen does not need to be tumor restricted; expression on normal and malignant prostatic cells is not a signi®cant limitation; (b) if targeting follows a radical prostatectomy there are no normal prostate epithelial cells remaining; (c) the presence of micrometastatic disease post surgery is indicated months to years prior to clinical symptoms using ultra-sensitive prostate speci®c antigen (PSA) assays thus providing unique opportunities for early intervention; and (d) upon therapeutic intervention, the monitoring of PSA levels provides a sense of ef®cacy and duration of response. For these reasons the generation of Mabs suitable for in vivo targeting of CaP is desirable.
The generation of Mabs to prostate cancer tissue, cell lines or prostatic¯uids can reveal novel prostate cancer associated antigens of potential biological importance such as PSA 2 , PSMA, 3 prostate speci®c protein (PSP-94) 4 and human kallikrein-2 (hK2). 5 There are also situations where the antibody reactivity pro®le is informative but the identity of the antigen remains elusive; PD-41, the most highly restricted CaP reactive antibody, is an excellent example. 6 Here we report on the generation of a new prostate reactive Mab, designated 107-1A4, which appears to be distinct from previously described Mabs and shows speci®c tumor targeting in preliminary in vivo studies.
Materials and methods

Hybridoma production and selection
A two phase immunization protocol was followed. For phase 1, a 10% w/v tissue suspension of normal prostate in PBS was prepared using a Virtis`45' homogenizer (Gardiner, NY). Female BALB/c pups were injected intra-peritoneally (i.p.) with 10 mL of the normal prostate homogenate on the day of birth, at 2 d, and with 30 mL at 6 d. Phase 2 began at six weeks of age using LNCaP cells as the immunogen. Con¯uent LNCaP cells were scraped from a T25¯ask and resuspended in 2.5 mL of Hanks Balanced Salt Solution (HBSS). The mice from phase 1 were injected i.p. with 2Â10 6 LNCaP cells in a 500 mL suspension three times at monthly intervals with a ®nal injection 3 d prior to sacri®ce and harvesting of the spleen for fusion. The fusion was performed as previously described using the SP2/0 mouse myeloma cell line. 7 Supernatants from rapidly growing clones were initially screened by enzyme-linked immunosorbent assay (ELISA) using the LNCaP cells as the reactive line and the Raji lymphoblastoma line as a negative control. Brie¯y, LNCaP cells were grown in 96-well plates (Costar, Cambridge, MA) until con¯uent and then ®xed for 15 min in a 0.15% glutaraldehyde/PBS solution. Raji cells being non-adherent were immobilized onto poly-Llysine coated 96 well plates using 10±12Â10 6 cells per plate. Plates were centrifuged to adhere the Raji cells to well bottoms, after which the cells were ®xed with glutaraldehyde in a manner identical to that for the LNCaP cells. After ®xation the plates were blocked with 2% BSA/PBS for 1 h at room temperature. The hybridoma supernatants (50 mL) were added and incubated for 30 min at room temperature. After washing, 50 mL of mouse IgG speci®c biotinylated horse anti-mouse antibody (BA-2080; Vector Laboratories, Burlingame, CA) was added at 2 mg/mL in 33% horse serum in 0.1% BSA/PBS and incubated for 30 min at room temperature. Controls consisted of MOPC-21, a IgG 1 monoclonal antibody with no reactivity to human antigens as a negative hybridoma supernatant control and serum from the mouse providing the spleen for fusion as a positive control. The Vectastain ABC kit (Vector Laboratories) and ABTS substrate (Zymed Laboratories, South San Francisco, CA) were used for the detection component of the ELISA. The supernatants which reacted to the LNCaP cells but not to the Raji cells were identi®ed and the respective hybridoma cultures were selected and further screened by immunohistochemistry against prostate and other tissues (vida infra). Highly reactive clones were subcloned and rescreened a minimum of three times. Hybridomas that remained positive by immunohistochemistry were recloned and used for ascites production. Monoclonal antibody isotypes were determined with the Isostrip isotyping kit (Boehringer Mannheim, Indianapolis, IN).
Ascites and monoclonal antibody puri®cation
BALB/c mice were primed with incomplete Freund's adjuvant two weeks prior to i.p. injection of 3Â10 6 actively growing hybridomas. Ascitic¯uid was collected and incubated at 37 C for 1 h, then at 4 C overnight. On the following day, the ascitic¯uid was centrifuged at 300 g for 20 min, the lipid layer was removed, and the ascites was stored at 720 C. Prior to immunoglobulin puri®cation, the ascitic uid was treated with BPA 1000 Biocryl beads (TosoHaas Bioseparation Specialists, Montgomeryville, PA) to remove contaminating lipids, nucleic acids, and cell debris. The IgG 1 Mabs were isolated from the ascites using a recombinant protein A column (Unisyn Technologies, Tustin, CA) according to the manufacturer's speci®cations. For those studies requiring a biotinylated Mab, biotinylation was accomplished with the Protein Biotinylation System kit (Gibco BRL, Grand Island, NY).
Immunoperoxidase (IP) staining
Frozen tissue sections of 5 mm thickness were prepared on poly-L-lysine coated slides (Sigma Chemical Co., St. Louis, MO) and ®xed in ice-cold acetone for 15 min. The sections were treated for 15 min with 0.03% H 2 O 2 to quench endogenous peroxidase and then blocked with 4% horse serum plus 4.8% chicken serum in PBS to prevent non-speci®c binding of the secondary antibody. An Avidin/Biotin Blocking kit (Vector Laboratories) was used to block endogenous biotin. The primary Mab was added at 10 mg/mL and incubated for 30 min at room temperature, followed by washing and addition of the biotinylated horse anti-mouse secondary antibody in 10% horse serum at 7.5 mg/mL. The secondary antibody was allowed to react for 30 min at room temperature, after which any unbound secondary antibody was removed by washing. Detection of the bound secondary antibody was accomplished with the Vectastain ABC kit (Vector Laboratories) and DAB (Research Genetics, Huntsville, AL) as the substrate. Tissues were counterstained with hematoxylin. Mab W6/32, which reacts to HLA A, B and C antigens, and MOPC-21 were used at 10 mg/mL as the positive and negative controls, respectively.
ELISAs
Cells
Reactivity of 107-1A4 to twenty three human carcinoma cell lines (vide infra) and human white blood cells was assessed by ELISA using the method described in the Hybridoma Production and Selection section. Mabs MOPC-21 and W6/32 were used as controls.
Membrane preparation and CaP homogenate
A LNCaP membrane preparation and CaP homogenate were checked for the presence of the 107-1A4 antigen by direct ELISA. LNCaP membranes were solubilized with 1% CHAPS detergent (Sigma) in the presence of 0.25 mM Pefabloc SC proteinase inhibitor (Boehringer Mannheim). A 10% w/v suspension of CaP homogenate was prepared in the same manner as the normal prostate homogenate previously described under the section Hybridoma Production and Selection. The membrane preparation was used in the range of 0.065 mg/mL±65 mg/mL total protein and CaP homogenate were serially diluted from 1:10± 1:1000. These preparations (100 mL/well) were coated onto EIA/RIA high binding plates (Costar) overnight at 4 C. The ELISAs were carried out as described above with the exception that positive controls consisted of Mab 7E11-C5, an antibody against PSMA, 8 and a panel of anti-PSA Mabs (15-19A2, 16-3A2, 22-8A2, 60-6A2 and 60-9A2) developed in our laboratory, 2 for the membrane and homogenate preparations, respectively. All test and control Mabs were used at a concentration of 10 mg/mL.
PSA, PSP-94, PAP and PSMA
Direct ELISAs were used to determine whether Mab 107-1A4 reacted to any of several known prostate associated proteins: PSA, 2 PSP-94, 9 and PAP (prostatic alkaline phosphatase). 10 These were puri®ed in our laboratory by standard methods and identity con®rmed by Western blot analysis. PSA was prepared at 0.35 mg/mL in PBS. The panel of anti-PSA Mabs previously described was used as the positive controls. PSP-94 was prepared at 0.5 mg/mL and the anti-PSP Mabs PSP-6 and PSP-19 (gifts of Dr G Wright) were used as the positive controls. 9 PAP was prepared at 2 mg/mL and anti-PAP Mab and polyclonal antibodies (Sigma, St. Louis, MO) were used as the positive controls. For these ELISAs, 100 mL of each protein preparation was immobilized to the wells of the EIA/RIA high-binding 96-well plates (Costar) for 1 h at room temperature. The de®ned primary antibodies were used at 10 mg/mL. 107-1A4 was used at 20, 10 and 1 mg/mL. MOPC-21 was used as a negative control.
A`sandwich' type ELISA was used to test 107-1A4 for reactivity to PSMA. EIA/RIA plates were coated with either 107-1A4 (10 mg/mL) or 7E11-C5 (10 mg/mL); 100 mL of the LNCaP membrane preparation containing PSMA was added to the wells at three total protein concentrations (0.065, 0.65 and 6.5 mg/mL). The plates were incubated for 2 h at room temperature and washed. Bound PSMA was detected by addition of biotinylated 7E11-C5 at 5 mg/mL. Wells coated directly with the LNCaP membrane preparation with detection by biotinylated 7E11-C5 were used as a positive control for con®rmation of PSMA presence in the preparation.
Indirect immuno¯uorescent (IDIF) staining
Twenty three human tumor cell lines (vide infra) were used in these studies. To determine whether steroids were required for the expression of the 107-1A4 antigen, LNCaP cells were additionally grown without steroids. Furthermore, to determine the stability of antigen expression, LNCaP cells were treated with 0.25% trypsin, 0.5 mM EDTA, 0.01% collagenase, or 0.01% hyaluronidase prior to staining. All cell lines were removed from¯asks by scraping and washed in PBS. An aliquot containing 5Â10 5 cells was removed and pelleted by centrifugation. These cells were resuspended in 200 mL of the primary antibody (107-1A4 or MOPC-21) at 10 mg/mL. The resulting suspension was incubated for 30 min at room temperature. The cells were washed in PBS and resuspended with a¯uorescein-conjugated goat anti-mouse antibody (Biosource International, Camarillo, CA) at 10 mg/mL and incubated for 30 min at room temperature. The cells were washed with PBS, resuspended in HBSS and mounted in a 1:1 solution of n-propyl gallate glycerol (5% w/v in HBSS) which reduces light-induced bleaching. A total of 300 cells were counted and evaluated per cell line.
Xenografts and biodistribution
All animal use and procedures were approved by the University of Washington's Animal Care Committee and performed according to NIH guidelines. Two CaP xenograft models were studied. In the ®rst, LuCaP 23.12 xenografts developed in our laboratory 11 were implanted subcutaneously in 4±5 week old, athymic male mice and resected at sacri®ce when the tumors ranged in size from 200±400 mm 3 . These xenografts were used for immunohistochemistry studies of 107-1A4 antigen expression. In the second model, xenografts were produced in male athymic mice by the subcutaneous injection of 2Â10 6 LNCaP cells in Matrigel (Collaborative Biomedical, Bedford, MA). 12 The mice bearing the LNCaP xenografts were used in the preliminary studies of in vivo biodistribution following con®rmation of antigen expression by immunohistochemistry.
Antibodies were radio-labeled using the Chloramine-T method and the integrity of the antibody labeling included HPLC simultaneous UV/radioisotope trace analysis and retention of antibody immunoreactivity by an LNCaP cell immunoassay as previously described. 13 For the biodistribution studies, mice with LNCaP xenografts of approximately 150 mm 3 were co-injected via the tail vein with 8 mg/100 mL PBS each of 131 I labeled 107-1A4 and 125 I labeled MOPC-21 (radionuclides: DuPont/NEN Wilmington, DE). Biodistribution data were obtained by determining the presence of the co-injected radionuclides in a panel of tissues harvested at sacri®ce (24, 72, 120 and 168 h post-injection) as previously described in detail. 14 
Results
Hybridoma production and selection
Following the initial screening of supernatants by ELISA, seven hybridoma clones highly reactive to LNCaP cells and not to Raji cells were selected for further evaluation. After two rounds of cloning and subsequent screening by immunohistology using a panel of OCT embedded human tissues, the Mab designated 107-1A4 was shown to have the highest speci®city for prostate. The 107-1A4 hybridomas were cloned another two times and the cells were then used for the production of antibody in ascites. Isotyping revealed that Mab 107-1A4 was an IgG 1 antibody. Puri®ed 107-1A4 antibody from ascitic¯uid was used for all of the studies described here.
Immunoperoxidase staining
Mab 107-1A4 reacted with all prostate tissues tested, benign prostate (N 30) and prostate carcinoma (N 22) ( Table 1) . Cellular staining was localized to the luminal epithelium and varied in intensity from 1±4 based on a scale of 0±4, where 0 no staining and 4 very dark staining (Figure 1 ). The percentage of epithelial cells stained with 107-1A4 ranged from 40±99% (median: 90%) in the sections of CaP, and from 50±99% (median: 90%) in sections of normal prostate. A similar range and median staining intensity were also observed in LNCaP and LuCaP 23 series xenografts (Table 1) . Table 1 also provides Mab 107-1A4 reactivity results using a panel of 46 normal human tissue samples (17 types) and three non-prostate carcinomas. Mab 107-1A4 did not react to any tissues in the panel with two minor exceptions, minimal reactivity was observed to renal cell carcinoma and the tubules of the normal kidney.
ELISAs
A panel of 23 cell lines encompassing 11 types of tumors plus white blood cells from normal donors were screened by ELISAs for reactivity with Mab 107-1A4 (Table 2) . Including three CaP lines, LNCaP, DU 145, and PC-3. Of the 23 lines tested only the LNCaP cells gave a positive reaction with 107-1A4.
An ELISA format was also used to determine whether the LNCaP membrane preparation and CaP homogenate contained the 107-1A4 antigen. There was no signi®cant reactivity with Mab 107-1A4. Positive controls, the 7E11-C5 and anti-PSA Mabs were highly reactive to the LNCaP membrane preparation and the CaP homogenate respectively. This would suggest that the 107-1A4 antigen was not PSMA nor PSA. To con®rm these observations two additional studies were performed. In the ®rst of these, we attempted again to assess reactivity of 107-1A4 with PSMA by using a sandwich ELISA format. The LNCaP membrane preparation was added to immobilized 7E11-C5 followed by biotinylated 107-1A4 or biotinylated 7E11-C5. The 107-1A4 con®guration did not result in a signal above background whereas the 7E11-C5 con®guration resulted in a substantial signal. To con®rm the absence of 107-1A4 reactivity with PSA, 107-1A4 was added to PSA coated wells in a direct ELISA format. No signal above background was obtained. In the ®nal series of ELISA studies we determined that 107-1A4 was not reactive with either PAP or PSP-94. The positive control antibodies yielded signals considerably above background.
IDIF
The reactivity of 107-1A4 with the 23 individual cell lines used in the ELISA panel was also evaluated by IDIF (Table 2 ). Similar reactivities were observed. 107-1A4 reacted strongly to the surface of LNCaP cells but not to DU-145 or PC-3. The staining appeared as a bright halo around the surface of each of the LNCaP cells (Figure 2 ). 107-1A4 reacted slightly with J-82, a transitional cell carcinoma of the bladder; approximately 5% of the cells were marginally¯uorescent. However, no reactivity was observed with the other bladder cancer cell lines nor with any other lines in the panel. 107-1A4 showed the same staining pattern and intensity with control LNCaP cells as those that underwent the following treatments: (a) 0.25% trypsin; (b) 0.5 mM EDTA; (c) 0.01% collagenase; or (d) 0.01% hyaluronidase. Similarly, there was no discernible difference in reactivity after growth of the LNCaP cells in the absence of testosterone. 
Discussion
The Mab 107-1A4, a murine IgG 1 antibody, described in this report, joins a limited number of antibodies showing selective reactivity to prostate epithelial membrane antigens. These will be contrasted to 107-1A4 subsequently, but of this group, only Mabs PD-41 (6), P25.48 and P 25.91 15 have been reported to be prostate cancer speci®c. Mab 107-1A4 reacted with 100% of the benign and malignant prostate tissues tested by immunohistochemistry and at the cellular level it had a median epithelial cell reactivity of 90%. Mab 107-1A4 also reacted strongly with the three CaP metastases included in this study: calvaria, mesentery and liver (Table 1) . Increased levels of staining, either intensity or percentage of positive cells did not correlate with tumor stage or grade. By staining intensity and pro®le, 107-1A4 reacted nearly identically with the LuCaP 23 xenograft series as it did with patient specimens. Furthermore, in the LNCaP xenografts we observed the same staining frequency (99%) as with cultured LNCaP cells. Collectively these staining patterns along with those showing an intense halo appearance on CaP cells in the live-cell¯uorescent studies suggest that this is a well-conserved, surface membrane antigen.
Previous efforts to generate prostate-reactive or kidney-reactive Mabs have revealed that these tissues, and on many cases the tumors arising from them, often share common antigens and antigenic epitopes, 16 similar to that being observed for Mab 107-1A4. For example, Mabs TURP-73, 17 Mabs 6.2 and 83.21 18 show high levels of reactivity with prostate tissue as well as reactivity with the proximal tubules of normal kidney, but no reactivity with tumorous kidney. Mab PR1 was reported as a prostate and CaP reactive Mab but it also showed reactivity with collecting duct cells of normal kidney. 19 Similarly, Mab 7E11-C5 which targets the PSM antigen in prostate and CaP cells also reacted with 2 out of 14 normal kidney sections but 0 of 3 RCC. 8 Finally, the Mab designated A6H, which we developed for targeting RCC, showed considerable reactivity to RCC and the proximal tubules 20 and, upon further characterization, to prostate epithelial cells (data unpublished). In some of these examples, it is possible that reactivity with the proximal tubules re¯ects binding to an absorbed antigen or antigen fragment rather than expression of the antigen by the proximal tubular cells. However, co-reactivity with these cells and RCC lessens the probability of that scenario. Mab 107-1A4 was reactive with proximal tubules, RCC tissue sections but not RCC cell lines. Therefore, we cannot predict with con®dence from these data whether the reactivity of Mab 107-1A4 is more likely due to an absorbed antigen by the proximal tubules or an expressed antigen which shares the epitope expressed on prostate epithelial cells. These determinations must await isolation and characterization of the 107-1A4 antigen.
Since LNCaP, which was used as the immunogen, expresses PSA, PAP, PSP-94 and PSMA an effort was made to speci®cally exclude these as potential targets of 107-1A4. Mab 107-1A4 was unreactive with puri®ed PSA, PAP or PSP-94. Since puri®ed PSMA was not available, a series of indirect studies were performed. The results strongly suggested that 107-1A4 does not react with PSMA.
To further support that the 107-1A4 antigen is not PSMA we observed no apparent change in 107-1A4 antigen expression by LNCaP cells upon withdrawal of steroids; in similar studies, PSMA was upregulated. 3 Moreover, when these studies were extended to the athymic mouse xenograft model, the LuCaP 23.12 tumors showed equivalent reactivity by immunoperoxidase staining with Mab 107-1A4 whether the tumors 17 and Mab PR1. 19 Thus there appears to be suf®cient evidence to suggest that a Mab identical to 107-1A4 has not been previously described.
The biodistribution results in these preliminary studies are encouraging and additional pre-clinical investigation is warranted. As stated previously, the targeting of metastatic prostate cancer offers several theoretical advantages over other solid tumors. Among these, two are prominent and highly distinctive. Firstly, targeting of the normal prostate, when present, is not a clinical limitation. Secondly, due to the exquisite ability of PSA assays to detect recurrent disease following radical prostatectomy, the opportunity exists to intervene with tumor targeting therapeutics at a time when there is truly minimal disease and subsequently, to monitor the therapeutic response by serially acquiring PSA levels. Despite these clear advantages, the hurdles that must be overcome to deliver therapeutic doses of immunoconjugates to the sites of metastatic disease are substantial. However, the clinical success in targeting CaP with anti-PSMA Mab Cyt-356 1 (the commercial version of 7E11-C5) demonstrates a degree of proof of principal and encouragement for future development of tumor targeting strategies especially with Mabs like 107-1A4 which show no bone marrow reactivity.
Efforts to isolate and characterize the 107-1A4 antigen have been unsuccessful by conventional approaches. Neither detergent extraction of membrane antigens nor homogenization of tissues or cells has yielded a signal on Western blot analysis. This suggests an alteration of the antigenic epitope or possible degradation of the antigen during processing and electrophoresis. A source of soluble antigen has been sought as a starting recourse for preparative af®nity chromatography but the antigen has not been detected in LNCaP culture supernatants, seminal¯uid, or serum. Among the Mabs generated to human tumors, dif®culty in identi®cation of the respective tumor associated antigen is quite common. For example, the anti-CaP Mab PD-41 is often referenced as the most tumor speci®c antibody developed, yet the antigen remains unde®ned despite exhaustive efforts since the initial report. 6 
Conclusions
The newly derived Mab 107-1A4 appears to recognize a novel prostate associated antigen. While the identity of the reactive antigen has been elusive, attempts to isolate and characterize the antigen further are continuing. The reactivity pattern of the Mab to other normal tissues is suf®ciently restrictive to suggest that it could have potential as a CaP targeting agent in man. Results from preliminary pre-clinical studies support the CaP targeting attributes of this Mab. Figure 3A represents the percent injected dose per gram of tissue resulting from an administered dose of approximately 38 uCi of radiolabeled 107-1A4. The percent injected dose per gram at 72 hours post injection was 22% in the LNCaP xenograft which resulted in a range from 3 times that of blood to 22 times that of muscle. In Figure 3B the results are provided as tissue to blood ratios with a maximal tumor to blood ratio of 3.5 at 120 hours post infusion. Negligible uptake was observed in all other acquired murine tissues.
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